Prospective Randomised Trial of Exercise and / or Antioxidants in COlorectal Cancer Patients Undergoing Surgery.
Launched by HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST · Oct 14, 2014
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
Study Design
This will be a prospective and randomised pilot clinical trial. For purposes of pragmatism, subjects and investigators will not be blinded to treatment allocation. The study is not blinded because it is impossible to blind investigators or patients to the exercise programme.
Patients undergoing major resectional surgery for colorectal cancer will be recruited from the Academic Surgical unit (ASU), Castle Hill Hospital. In total, 60 participants will be recruited for this pilot study and randomly allocated into 2 groups as outlined below.
The study will necessitate all partic...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients with colorectal cancer listed for elective resection surgery who have consented to participate in the study.
- Exclusion Criteria:
- • History of unstable angina/unstable coronary artery disease or a heart attack in the previous month
- • Any heart related disease including but not limited to aortic stenosis, pericarditis or any thromboembolic disease
- • Severe Infections and fever
- • Uncontrolled metabolic diseases
- • Uncontrolled asthma
- • Acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise
- • Resting heart rate of more than 120 BPM
- • Systolic blood pressure of more than 180 mm Hg or diastolic blood pressure of more than 110 mm Hg
- • Recent cerebrovascular accident
- • Pregnancy
- • Preexisting severe physical disability
- • Age \<18 years
- • Unwilling to allow their GP to be informed of their participation in the study
About Hull University Teaching Hospitals Nhs Trust
Hull University Teaching Hospitals NHS Trust is a leading healthcare organization dedicated to delivering high-quality patient care, education, and research. Located in Hull, England, the Trust encompasses a range of hospitals and healthcare services, providing a comprehensive spectrum of clinical specialties. With a strong commitment to advancing medical science, the Trust actively sponsors and conducts clinical trials that aim to improve patient outcomes and contribute to evidence-based practice. By collaborating with academic partners and leveraging its state-of-the-art facilities, Hull University Teaching Hospitals NHS Trust fosters an innovative research environment that prioritizes patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hull, East Yorkshire, United Kingdom
Patients applied
Trial Officials
John Hartley, MD FRCS
Principal Investigator
Hull and East Yorkshire NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials